Who are Course B3 +Vin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Course A1 + Vin, Course A3 + Vin, Placebo + R-CHOP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/course-b3-vin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Course B3 +Vin — Competitive Intelligence Brief

Course B3 +Vin (Course B3 +Vin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-agent chemotherapy combination. Area: Oncology.

phase 3 Multi-agent chemotherapy combination Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Course B3 +Vin (Course B3 +Vin) — Children's Cancer Group, China. Course B3 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents to disrupt cancer cell division and induce apoptosis in pediatric malignancies.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Course B3 +Vin TARGET	Course B3 +Vin	Children's Cancer Group, China	phase 3	Multi-agent chemotherapy combination
Course A1 + Vin	Course A1 + Vin	Children's Cancer Group, China	phase 3	Multi-agent chemotherapy combination
Course A3 + Vin	Course A3 + Vin	Children's Cancer Group, China	phase 3	Multi-agent chemotherapy combination
Placebo + R-CHOP	Placebo + R-CHOP	Beijing InnoCare Pharma Tech Co., Ltd.	phase 3	Monoclonal antibody + multi-agent chemotherapy combination	CD20 (rituximab component); multiple targets (CHOP chemotherapy)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-agent chemotherapy combination class)

Children's Cancer Group, China · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Course B3 +Vin — Competitive Intelligence Brief. https://druglandscape.com/ci/course-b3-vin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab